SG11202108449SA - Use of oncolytic viruses for the treatment of cancer - Google Patents
Use of oncolytic viruses for the treatment of cancerInfo
- Publication number
- SG11202108449SA SG11202108449SA SG11202108449SA SG11202108449SA SG11202108449SA SG 11202108449S A SG11202108449S A SG 11202108449SA SG 11202108449S A SG11202108449S A SG 11202108449SA SG 11202108449S A SG11202108449S A SG 11202108449SA SG 11202108449S A SG11202108449S A SG 11202108449SA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- treatment
- oncolytic viruses
- oncolytic
- viruses
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16671—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962813961P | 2019-03-05 | 2019-03-05 | |
PCT/US2020/020793 WO2020180864A1 (en) | 2019-03-05 | 2020-03-03 | Use of oncolytic viruses for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202108449SA true SG11202108449SA (en) | 2021-09-29 |
Family
ID=70289836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202108449SA SG11202108449SA (en) | 2019-03-05 | 2020-03-03 | Use of oncolytic viruses for the treatment of cancer |
Country Status (17)
Country | Link |
---|---|
US (1) | US20220090133A1 (en) |
EP (1) | EP3935182A1 (en) |
JP (1) | JP2022522817A (en) |
KR (1) | KR20210135532A (en) |
CN (1) | CN113439123A (en) |
AR (1) | AR120048A1 (en) |
AU (1) | AU2020232264A1 (en) |
BR (1) | BR112021017551A2 (en) |
CA (1) | CA3131529A1 (en) |
CL (1) | CL2021002307A1 (en) |
EA (1) | EA202192420A1 (en) |
IL (1) | IL285221A (en) |
MX (1) | MX2021010458A (en) |
SG (1) | SG11202108449SA (en) |
TW (1) | TW202100542A (en) |
UY (1) | UY38603A (en) |
WO (1) | WO2020180864A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4313094A1 (en) * | 2021-03-24 | 2024-02-07 | Virogin Biotech Canada Ltd | Transcriptional and translational dual regulated oncolytic herpes simplex virus vectors |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6770274B1 (en) | 1990-09-14 | 2004-08-03 | The General Hospital Corporation | Viral mutant HSV mediated destruction of neoplastic cells |
US6699468B1 (en) | 1994-06-23 | 2004-03-02 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
US5728379A (en) | 1994-06-23 | 1998-03-17 | Georgetown University | Tumor- or cell-specific herpes simplex virus replication |
US5585096A (en) | 1994-06-23 | 1996-12-17 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
US5824318A (en) | 1996-07-24 | 1998-10-20 | American Cyanamid Company | Avirulent herpetic viruses useful as tumoricidal agents and vaccines |
US6379674B1 (en) | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
EP1141338A4 (en) | 1998-12-31 | 2002-09-25 | Arch Dev Corp | Recombinant herpes simplex virus useful for treating neoplastic disease |
AU2905199A (en) | 1999-03-15 | 2000-10-04 | Trustees Of The University Of Pennsylvania, The | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
US6764675B1 (en) | 1999-06-08 | 2004-07-20 | The Uab Research Foundation | Herpes simplex virus expressing foreign genes and method for treating cancers therewith |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
KR100942863B1 (en) | 1999-08-24 | 2010-02-17 | 메다렉스, 인코포레이티드 | Human ctla-4 antibodies and their uses |
GB0001475D0 (en) * | 2000-01-21 | 2000-03-15 | Neurovex Ltd | Virus strains |
BRPI0107736B8 (en) | 2000-01-21 | 2021-05-25 | Biovex Ltd | hsv1 js1 strain, pharmaceutical composition, and use of an hsv1 js1 strain |
AU2002306919B2 (en) | 2001-03-27 | 2007-11-22 | Tomoki Todo | Viral vectors and their use in therapeutic methods |
WO2003042402A2 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
US7521051B2 (en) | 2002-12-23 | 2009-04-21 | Medimmune Limited | Methods of upmodulating adaptive immune response using anti-PD-1 antibodies |
WO2006002394A2 (en) | 2004-06-24 | 2006-01-05 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
AU2006244885B2 (en) | 2005-05-09 | 2011-03-31 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
HUE026039T2 (en) | 2005-07-01 | 2016-05-30 | Squibb & Sons Llc | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
SI2170959T1 (en) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Pd-1 binding proteins |
KR102097887B1 (en) | 2008-09-26 | 2020-04-06 | 다나-파버 캔서 인스티튜트 인크. | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
CN114835812A (en) | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | anti-PD-L1 antibodies and their use for enhancing T cell function |
EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | Simultaneous inhibition of pd-l1/pd-l2 |
WO2011082400A2 (en) | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
CA2802344C (en) | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
WO2013006795A2 (en) | 2011-07-07 | 2013-01-10 | Humanitas International Foundation | Antiviral compositions and methods of their use |
ES2704632T3 (en) | 2011-09-08 | 2019-03-19 | Univ New York | Oncolytic herpes simplex virus and its therapeutic uses |
JP7038664B2 (en) | 2016-01-08 | 2022-03-18 | レプリミュン リミテッド | Manipulated oncolytic virus |
WO2017181420A1 (en) | 2016-04-22 | 2017-10-26 | Immuno Vir Co., Limited | CONSTRUCTION OF ONCOLYTIC HERPES SIMPLEX VIRUSES (oHSV) OBLIGATE VECTOR AND CONSTRUCTS FOR CANCER THERAPY |
SG11201811600PA (en) | 2016-06-30 | 2019-01-30 | Oncorus Inc | Pseudotyped oncolytic viral delivery of therapeutic polypeptides |
WO2018026872A1 (en) | 2016-08-01 | 2018-02-08 | Virogin Biotech Canada Ltd | Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules |
GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
JOP20190256A1 (en) * | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | Newcastle disease viruses and uses thereof |
CN111212656A (en) * | 2017-07-26 | 2020-05-29 | 昂克诺斯公司 | Oncolytic viral vectors and uses thereof |
AU2018314227A1 (en) * | 2017-08-07 | 2020-02-06 | Amgen Inc. | Treatment of triple negative breast cancer or colorectal cancer with liver metastases with an anti PD-L1 antibody and an oncolytic virus |
CA3122431A1 (en) * | 2018-01-05 | 2019-07-11 | Turnstone Biologics Corp. | Modified orthopoxvirus vectors |
CN108315351B (en) * | 2018-04-12 | 2022-03-22 | 济南海湾生物工程有限公司 | Mammalian cell expression vector for industrial production |
CN108635380A (en) * | 2018-04-13 | 2018-10-12 | 北京唯源立康生物科技有限公司 | Recombination oncolytic virus composition and its application in preparing the drug for treating tumour |
MX2021003013A (en) * | 2018-09-15 | 2021-08-11 | Memorial Sloan Kettering Cancer Center | Recombinant poxviruses for cancer immunotherapy. |
-
2020
- 2020-03-03 JP JP2021551929A patent/JP2022522817A/en active Pending
- 2020-03-03 CA CA3131529A patent/CA3131529A1/en active Pending
- 2020-03-03 BR BR112021017551A patent/BR112021017551A2/en unknown
- 2020-03-03 EP EP20719515.7A patent/EP3935182A1/en active Pending
- 2020-03-03 US US17/435,768 patent/US20220090133A1/en active Pending
- 2020-03-03 SG SG11202108449SA patent/SG11202108449SA/en unknown
- 2020-03-03 AU AU2020232264A patent/AU2020232264A1/en active Pending
- 2020-03-03 WO PCT/US2020/020793 patent/WO2020180864A1/en active Application Filing
- 2020-03-03 EA EA202192420A patent/EA202192420A1/en unknown
- 2020-03-03 KR KR1020217030518A patent/KR20210135532A/en unknown
- 2020-03-03 CN CN202080014516.5A patent/CN113439123A/en active Pending
- 2020-03-03 MX MX2021010458A patent/MX2021010458A/en unknown
- 2020-03-05 UY UY0001038603A patent/UY38603A/en unknown
- 2020-03-05 AR ARP200100619A patent/AR120048A1/en unknown
- 2020-03-05 TW TW109107309A patent/TW202100542A/en unknown
-
2021
- 2021-07-29 IL IL285221A patent/IL285221A/en unknown
- 2021-09-03 CL CL2021002307A patent/CL2021002307A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL285221A (en) | 2021-09-30 |
TW202100542A (en) | 2021-01-01 |
CL2021002307A1 (en) | 2022-05-27 |
CA3131529A1 (en) | 2020-09-10 |
EA202192420A1 (en) | 2021-12-13 |
US20220090133A1 (en) | 2022-03-24 |
JP2022522817A (en) | 2022-04-20 |
AU2020232264A1 (en) | 2021-08-26 |
AR120048A1 (en) | 2022-02-02 |
EP3935182A1 (en) | 2022-01-12 |
BR112021017551A2 (en) | 2021-11-09 |
UY38603A (en) | 2020-08-31 |
CN113439123A (en) | 2021-09-24 |
KR20210135532A (en) | 2021-11-15 |
WO2020180864A1 (en) | 2020-09-10 |
MX2021010458A (en) | 2021-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3781564C0 (en) | Pyridazine derivatives for the treatment of cancer | |
HK1247129A1 (en) | Combination therapy for the treatment of cancer | |
HK1251475A1 (en) | Combination therapy for the treatment of cancer | |
IL267795A (en) | Combination therapy for the treatment of cancer | |
IL253243A0 (en) | Combined preparations for the treatment of cancer or infection | |
EP3577132A4 (en) | Oncolytic virus therapy | |
EP3288957A4 (en) | Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer | |
EP3212658A4 (en) | 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer | |
EP3134423A4 (en) | 2' -disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer | |
ZA202206743B (en) | Therapy for the treatment of cancer | |
IL281845A (en) | Combination therapy for the treatment of cancer | |
GB201903546D0 (en) | Cancer treatment | |
IL284162A (en) | Combination therapy for the treatment of cancer | |
IL287652A (en) | Cancer treatment | |
IL266993A (en) | Combination therapy for the treatment of cancer | |
IL285466A (en) | Cancer treatment | |
IL285221A (en) | Use of oncolytic viruses for the treatment of cancer | |
EP3875119A4 (en) | Oncolytic virus for cancer therapy | |
GB201812647D0 (en) | Viral vectors and methods for the prevention or treatment of cancer | |
GB201803197D0 (en) | Viral treatment | |
EP3642335A4 (en) | Recombinant oncolytic viruses for treatment of metastatic cancers | |
GB201816547D0 (en) | Oncolytic virus for the treatment of cancer | |
IL288035A (en) | Cancer treatment | |
IL282313A (en) | Abituzumab for the treatment of colorectal cancer | |
EP3894423A4 (en) | Dna aptamers and use thereof for the treatment of cancer |